Price (delayed)
$2.03
Market cap
$116.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.31
Enterprise value
$132.79M
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to
There are no recent dividends present for PLX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.